Fin Trust Capital Advisors, LLC Crispr Therapeutics Ag Transaction History
Fin Trust Capital Advisors, LLC
- $577 Million
- Q3 2024
A detailed history of Fin Trust Capital Advisors, LLC transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Fin Trust Capital Advisors, LLC holds 180 shares of CRSP stock, worth $6,658. This represents 0.0% of its overall portfolio holdings.
Number of Shares
180
Previous 180
-0.0%
Holding current value
$6,658
Previous $9,000
11.11%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding CRSP
# of Institutions
488Shares Held
64.1MCall Options Held
1.64MPut Options Held
1.93M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl8.97MShares$332 Million3.09% of portfolio
-
Capital International Investors Los Angeles, CA8.74MShares$323 Million0.07% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD3.81MShares$141 Million0.09% of portfolio
-
Black Rock Inc. New York, NY2.78MShares$103 Million0.0% of portfolio
-
Sumitomo Mitsui Trust Holdings, Inc.2.75MShares$102 Million0.07% of portfolio
About CRISPR Therapeutics AG
- Ticker CRSP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 78,009,296
- Market Cap $2.89B
- Description
- CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....